Literature DB >> 29520857

Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.

Malak M Alame1, Dina J Chamsy2, Hassan Zaraket3.   

Abstract

A 30-year-old pregnant female presented with a 2-week history of pityriasis rosea-like eruption. The rash started 2 days after the patient had started taking ondansetron 8 mg for alleviation of moderate-to-severe nausea and vomiting of pregnancy. Physical examination revealed erythematous papulosquamous lesions characterized by annular scaly margins and a dusky centre over the arms, chest, abdomen, lower back and legs. The rash did not involve the palms, sole or mucous membranes, and no lesions were observed on the lymph nodes. Ondansetron was discontinued. The rash ceased to spread and started to disappear within 2 weeks with full resolution noted after 1 month. Analysis of the case using the Naranjo adverse drug reaction probability scale indicated that ondansetron was the probable cause of the pityriasis rosea-like eruption. This is the first case report of pityriasis rosea related to ondansetron therapy.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  Pityriasis rosea; adevse reaction; ondansetron; pregnancy

Mesh:

Substances:

Year:  2018        PMID: 29520857      PMCID: PMC5903224          DOI: 10.1111/bcp.13560

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Delayed diagnosis of anaphylaxis secondary to ondansetron: A case report.

Authors:  Preeti Goyal; Kaggere Paramesh; Sarang Puranik; Mark Proctor; Mihir Sanghvi
Journal:  Eur J Anaesthesiol       Date:  2016-02       Impact factor: 4.330

2.  Diagnosis and management of pityriasis rosea.

Authors:  Kathy VanRavenstein; Barbara J Edlund
Journal:  Nurse Pract       Date:  2017-01-20

3.  IgE-mediated hypersensitivity to ondansetron and safe use of palonosetron.

Authors:  John Leung; Autumn Guyer; Aleena Banerji
Journal:  J Allergy Clin Immunol Pract       Date:  2013-06-25

4.  Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7.

Authors:  Francesco Broccolo; Francesco Drago; Anna M Careddu; Chiara Foglieni; Laura Turbino; Clementina E Cocuzza; Carlo Gelmetti; Paolo Lusso; Alfredo E Rebora; Mauro S Malnati
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2.

Authors:  S Bernand; E P Scheidegger; R Dummer; G Burg
Journal:  Dermatology       Date:  2000       Impact factor: 5.366

7.  Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.

Authors:  Malak M Alame; Dina J Chamsy; Hassan Zaraket
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

Review 8.  Ondansetron and pregnancy: Understanding the data.

Authors:  Debra Kennedy
Journal:  Obstet Med       Date:  2015-12-23

9.  A Rare Case of Fixed Drug Eruption due to Ondansetron.

Authors:  Aditi Maitra; Shashwat Bhattacharyya; Sabyasachi Paik; Prerna Pathak; Santanu Kumar Tripathi
Journal:  Iran J Med Sci       Date:  2017-09

10.  Hypersensitivity to intravenous ondansetron: a case report.

Authors:  Karishma K Mehra; Nithya J Gogtay; Rohan Ainchwar; Lata S Bichile
Journal:  J Med Case Rep       Date:  2008-08-14
View more
  3 in total

1.  Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.

Authors:  Malak M Alame; Dina J Chamsy; Hassan Zaraket
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

Review 2.  Pityriasis rosea in pregnancy: A case series and literature review.

Authors:  Lena Wenger-Oehn; Thomas Graier; Christina Ambros-Rudolph; Robert Müllegger; Christina Bittighofer; Peter Wolf; Angelika Hofer
Journal:  J Dtsch Dermatol Ges       Date:  2022-05-26       Impact factor: 5.231

3.  Reply: Commentary on letter to the editor from Drago et al.

Authors:  Carole Bitar; Andrea Murina
Journal:  JAAD Case Rep       Date:  2018-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.